NCT03377231 is a Phase 4 clinical trial of Stratamark® in Stretch Mark, sponsored by Stratpharma AG.

Who is sponsoring NCT03377231?

NCT03377231 is sponsored by Stratpharma AG.

What drugs are being tested in NCT03377231?

Interventions in NCT03377231: Stratamark®.

What condition does NCT03377231 study?

NCT03377231 studies Stretch Mark.

Is NCT03377231 still recruiting?

NCT03377231 is currently completed. Last updated 20 December 2017.

Last reviewed 2017-12-20 · How we verify

NCT03377231

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prevention and Treatment of Stretch Marks With Stratamark™

Completed Phase 4 Last updated 20 December 2017

What this trial tests

Phase 4 trial testing Stratamark® in Stretch Mark in 272 participants. Completed in 16 May 2016.

Timeline

11 July 2013

Primary endpoint
16 May 2016

16 May 2016

Quick facts

Lead sponsor	Stratpharma AG
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	other
Enrollment	272
Start date	11 July 2013
Primary completion	16 May 2016
Estimated completion	16 May 2016

Drugs / interventions tested

Stratamark®

Conditions studied

Stretch Mark — all drugs for Stretch Mark →

Sponsor

Stratpharma AG — full company profile →

Who can join

18 and older, female only, with Stretch Mark. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Stretch marks (striae distensae) are a form of scarring that is a natural result of pregnancy, obesity and in some instances occur due to puberty or steroid use. For some people, the stretch marks do not cause a problem, but in many circumstances they can cause physical symptoms such as itchiness, tenderness and pain. For many people stretch marks are also embarrassing and can have detrimental effects on a patient's mood and self-esteem. Stretch marks that result from pregnancy most commonly occur on the abdomen, breasts and thighs. Topical silicone gel was developed nearly thirty years ago to be used in the treatment of widespread hypertrophic scars (abnormal scars, which may be red or raised/depressed itchy or painful). Since this time it has been used successfully on most scar types. . Since stretch marks are a form of scarring it is thought that topical silicone gel may be helpful for this scar type also. Stratamark™ has been developed using different forms of silicone polymers, in a gel format, that dries to form a very thin and flexible silicone gel sheet making it a convenient therapy for the treatment and prevention of stretch marks. The aim of this clinical research study is to prove or disprove the efficacy, safety and tolerability of Stratamark™ in the prevention and treatment of stretch marks. In addition, the knowledge gained from this study may be of benefit to many future patients

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Stratpharma AG trials

Trials by the same sponsor.

NCT05810194 — Retrospective Cohort Study Comparing a Novel Gel Dressing vs SoC in the Treatment of Radiation Dermatitis · completed
NCT05614557 — Impact of Silicon-based Formulations on Wound Healing of Laser-induced Microscopic Skin Lesions · NA · completed
NCT05553392 — StrataXRT Versus Aquaphor for the Prevention and Management of Radiation Dermatitis · NA · terminated
NCT05432154 — An Innovative Silicone Wound Dressing for the Management of Atrophic Vaginitis · NA · completed
NCT05396261 — a Flexible Wound Dressing for the Management of Genital Skin Conditions · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03377231 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Stratpharma AG
Last refreshed: 20 December 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03377231.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing